198 related articles for article (PubMed ID: 31449404)
1. Smoothed Potential MD Simulations for Dissociation Kinetics of Etoposide To Unravel Isoform Specificity in Targeting Human Topoisomerase II.
Kuriappan JA; Osheroff N; De Vivo M
J Chem Inf Model; 2019 Sep; 59(9):4007-4017. PubMed ID: 31449404
[TBL] [Abstract][Full Text] [Related]
2. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Morgan SE; Cadena RS; Raimondi SC; Beck WT
Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
[TBL] [Abstract][Full Text] [Related]
3. Effect of cellular ATP depletion on topoisomerase II poisons. Abrogation Of cleavable-complex formation by etoposide but not by amsacrine.
Sorensen M; Sehested M; Jensen PB
Mol Pharmacol; 1999 Mar; 55(3):424-31. PubMed ID: 10051525
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibition redistributes topoisomerase IIβ from heterochromatin to euchromatin.
Cowell IG; Papageorgiou N; Padget K; Watters GP; Austin CA
Nucleus; 2011; 2(1):61-71. PubMed ID: 21647300
[TBL] [Abstract][Full Text] [Related]
5. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA
Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921
[TBL] [Abstract][Full Text] [Related]
6. The impact of the human DNA topoisomerase II C-terminal domain on activity.
Meczes EL; Gilroy KL; West KL; Austin CA
PLoS One; 2008 Mar; 3(3):e1754. PubMed ID: 18335031
[TBL] [Abstract][Full Text] [Related]
7. Novel, Potent, and Druglike Tetrahydroquinazoline Inhibitor That Is Highly Selective for Human Topoisomerase II α over β.
Ortega JA; Arencibia JM; Minniti E; Byl JAW; Franco-Ulloa S; Borgogno M; Genna V; Summa M; Bertozzi SM; Bertorelli R; Armirotti A; Minarini A; Sissi C; Osheroff N; De Vivo M
J Med Chem; 2020 Nov; 63(21):12873-12886. PubMed ID: 33079544
[TBL] [Abstract][Full Text] [Related]
8. Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.
Elsea SH; Westergaard M; Burden DA; Lomenick JP; Osheroff N
Biochemistry; 1997 Mar; 36(10):2919-24. PubMed ID: 9062121
[TBL] [Abstract][Full Text] [Related]
9. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.
Järvinen TA; Tanner M; Rantanen V; Bärlund M; Borg A; Grénman S; Isola J
Am J Pathol; 2000 Mar; 156(3):839-47. PubMed ID: 10702400
[TBL] [Abstract][Full Text] [Related]
10. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
11. Etoposide targets topoisomerase IIalpha and IIbeta in leukemic cells: isoform-specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique.
Willmore E; Frank AJ; Padget K; Tilby MJ; Austin CA
Mol Pharmacol; 1998 Jul; 54(1):78-85. PubMed ID: 9658192
[TBL] [Abstract][Full Text] [Related]
12. Distinct roles of Topoisomerase II isoforms: DNA damage accelerating alpha, double strand break repair promoting beta.
Mandraju RK; Kannapiran P; Kondapi AK
Arch Biochem Biophys; 2008 Feb; 470(1):27-34. PubMed ID: 18021738
[TBL] [Abstract][Full Text] [Related]
13. Topoisomerase II.etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes.
Burden DA; Kingma PS; Froelich-Ammon SJ; Bjornsti MA; Patchan MW; Thompson RB; Osheroff N
J Biol Chem; 1996 Nov; 271(46):29238-44. PubMed ID: 8910583
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of topoisomerase II-targeted anticancer agents reflects the persistence of drug-induced cleavage complexes in cells.
Bandele OJ; Osheroff N
Biochemistry; 2008 Nov; 47(45):11900-8. PubMed ID: 18922022
[TBL] [Abstract][Full Text] [Related]
15. Effect of a single nucleotide polymorphism in the murine double minute 2 promoter (SNP309) on the sensitivity to topoisomerase II-targeting drugs.
Nayak MS; Yang JM; Hait WN
Cancer Res; 2007 Jun; 67(12):5831-9. PubMed ID: 17575151
[TBL] [Abstract][Full Text] [Related]
16. Molecular dynamics simulations of sulfone derivatives in complex with DNA topoisomerase IIα ATPase domain.
Verma K; Mahalapbutr P; Auepattanapong A; Khaikate O; Kuhakarn C; Takahashi K; Rungrotmongkol T
J Biomol Struct Dyn; 2022 Mar; 40(4):1692-1701. PubMed ID: 33089727
[TBL] [Abstract][Full Text] [Related]
17. Alternative RNA Processing of Topoisomerase IIα in Etoposide-Resistant Human Leukemia K562 Cells: Intron Retention Results in a Novel C-Terminal Truncated 90-kDa Isoform.
Kanagasabai R; Serdar L; Karmahapatra S; Kientz CA; Ellis J; Ritke MK; Elton TS; Yalowich JC
J Pharmacol Exp Ther; 2017 Jan; 360(1):152-163. PubMed ID: 27974648
[TBL] [Abstract][Full Text] [Related]
18. Decreased levels of topoisomerase II alpha in human renal cell carcinoma lines resistant to etoposide.
Scheltema JM; Romijn JC; van Steenbrugge GJ; Beck WT; Schröder FH; Mickisch GH
J Cancer Res Clin Oncol; 1997; 123(10):546-54. PubMed ID: 9393588
[TBL] [Abstract][Full Text] [Related]
19. Binding of etoposide to topoisomerase II in the absence of DNA: decreased affinity as a mechanism of drug resistance.
Kingma PS; Burden DA; Osheroff N
Biochemistry; 1999 Mar; 38(12):3457-61. PubMed ID: 10090731
[TBL] [Abstract][Full Text] [Related]
20. Coupling the core of the anticancer drug etoposide to an oligonucleotide induces topoisomerase II-mediated cleavage at specific DNA sequences.
Infante Lara L; Fenner S; Ratcliffe S; Isidro-Llobet A; Hann M; Bax B; Osheroff N
Nucleic Acids Res; 2018 Mar; 46(5):2218-2233. PubMed ID: 29447373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
